Pieris Pharmaceuticals, Inc. (PIRS)

Pieris Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	42.81	25.9	31.42	29.32	46.28
Revenue Growth (YoY)	65.28%	-17.56%	7.14%	-36.64%	59.03%
Gross Profit	42.81	25.9	31.42	29.32	46.28
Selling, General & Admin	16.85	16.39	16.59	16.71	18.44
Research & Development	41.8	52.98	66.66	46.53	55
Other Operating Expenses	13.91	0	0	0	0
Operating Expenses	72.57	69.38	83.25	63.24	73.44
Operating Income	-29.76	-43.47	-51.83	-33.92	-27.16
Other Expense / Income	-5.21	-10.2	-6.09	3.15	-1.69
Pretax Income	-24.54	-33.28	-45.74	-37.07	-25.47
Income Tax	0	0	0	0.16	0
Net Income	-24.54	-33.28	-45.74	-37.23	-25.47
Preferred Dividends	0	0	0	0	2.83
Net Income Common	-24.54	-33.28	-45.74	-37.23	-28.3
Shares Outstanding (Basic)	1	1	1	1	1
Shares Outstanding (Diluted)	1	1	1	1	1
Shares Change	21.43%	14.91%	18.48%	7.62%	-4.63%
EPS (Basic)	-21.60	-36.00	-56.80	-54.40	-44.80
EPS (Diluted)	-21.60	-36.00	-56.80	-54.40	-44.80
Free Cash Flow	-53.99	-60.97	-8.61	-48.62	-54.93
Free Cash Flow Per Share	-47.96	-65.76	-10.67	-71.40	-86.80
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-69.51%	-167.84%	-164.97%	-115.68%	-58.68%
Profit Margin	-57.33%	-128.47%	-145.58%	-126.97%	-61.15%
Free Cash Flow Margin	-126.12%	-235.40%	-27.40%	-165.82%	-118.69%
EBITDA	-22.76	-30.5	-43.37	-34.94	-24.43
EBITDA Margin	-53.17%	-117.74%	-138.04%	-119.15%	-52.79%
Depreciation & Amortization	1.78	2.78	2.37	2.13	1.04
EBIT	-24.54	-33.28	-45.74	-37.07	-25.47
EBIT Margin	-57.33%	-128.47%	-145.58%	-126.41%	-55.03%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).